ARASENS Darolutamide vs Placebo

[janebob99]

This Kaplan-Meier plot show the Castration - Resistant Prostate Cancer Free survival probability (%) for two groups: (A) Darolutamide + ADT + Docetaxel, versus (B) Placebo + ADT + Docetaxel, taken at two different times: 2 years and 4 years.

There is a very large increase in survival probability with the Darolutamide group (A) vs Placebo group (B) at both 2 years and at 4 years. The multiplier is about a factor of 2 better for Darolutamide + ADT + Docetaxe, compared to Placebo + ADT + Docetaxel.

The Cohort was High Risk men.

ascopubs.org/doi/10.1200/JC...

[Maxone73]

from the top of my head ( not going to check one of my old posts right now) the latest ARASENS update talked about progression free survival median not reached (so more than 50% of patients were still free of progression) at 43.7 months. And so was the time to castration resistance median. And from the graphics in the article you posted, even after 57 months median was not reached. Very good news!

[janebob99 in reply to Maxone73]

Thanks !

It would be interesting if someone compared Darolutamide alone to Darolutamide + Lupron, like they did with enzalutamide. I would expect similar results, since both are anti-androgen drugs.

[Maxone73 in reply to janebob99]

well if you like, they did a triplet comparison with abiraterone

sciencedirect.com/science/a...

ARASENS still perform better

[janebob99 in reply to Maxone73]

99% reduction in PSA is an excellent response!

Thanks for the article.

[Maxone73 in reply to janebob99]

There you go: ARAMON and ARASTEP, I knew there was something

urotoday.com/video-lectures...

[janebob99 in reply to Maxone73]

Very exciting! Thanks for the link.

I'm very interested in the darolutamide monotherapy trial.

[kainasar]

Problem is - this data shows efficacy in use for HSPC or mHSPC not for mCPRC or nmCPRC.

[street-air in reply to kainasar]

why is that a problem?